Stock Markets
Daily Stock Markets News

Sanders’ long COVID funding bill misses opportunity to aid a similar chronic


Sen. Bernie Sanders’ (I-Vt.) recent call for $10 billion in research grants over ten years for long COVID is a worthy initiative, yet we are deeply disappointed the senator is limiting his focus to long COVID. Millions of victims of infection-associated chronic conditions have been waiting decades for the federal government to fund research to improve diagnosis and develop therapies.

A handful of diseases that, like long COVID, are chronic and debilitating, each of which affects the central nervous system and result from infection, have been neglected. All of them existed prior to the COVID-19 outbreak of 2020. The most neglected of these is also the most common and among the most disabling of all: ME/CFS. This is a compromise name for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Formerly known as ME, the severity of the illness was dismissed and victims were ridiculed in the popular press after CDC renamed the disease “chronic fatigue syndrome” in 1988.

We ask that Sanders specifically name ME/CFS in his bill and include a generous budget for ME/CFS research, one commensurate with the burden of the illness. In spite of the fact that ME/CFS is common, afflicting 1.3 percent of the American population and an estimated 67 million people globally, federal funding levels to study it have been shockingly low. Before COVID-19 arrived, the economic cost of ME/CFS was over $36 billion a year

One reason for this neglect has been the public’s failure to understand how high their chances of acquiring ME/CFS are and just how serious it actually is. Impaired cognition, a major feature of the disease, results in a devastating loss of mental acuity that interferes with the ability to maintain a semblance of normal life. ME/CFS victims find they cannot exert themselves for the simplest demands of daily life without heightening all their symptoms. Indeed, patients aren’t “tired” — they’re often too weak to stand or walk unaided. Another crippling problem is a lack of blood flow to the brain, a serious circulation defect that can prevent patients from remaining upright without blacking out.

Morbidity studies suggest the physical suffering in ME/CFS is enormous, worse than multiple sclerosis or congestive heart failure, for instance. Recovery is vanishingly rare, leaving patients to struggle for decades.

Any discussion of the toll of ME/CFS would be remiss without mentioning the surfeit of suicide observed in this population. Final letters from patients typically invoke the specter of permanent suffering without medical care.

A tantalizing piece of the ME/CFS puzzle has been its history of discrete outbreaks all over the world during the last century. One of the earliest occurred in Los Angeles in 1934. Two-hundred out of 1,500 members of the Los Angeles County General Hospital staff fell ill, most of them permanently. Outbreaks in Iceland, New Zealand, the UK, and the U.S. followed. A combination of indifference, dismissal of patients’ concerns and inadequate technology resulted in a failure to identify the responsible viruses. Ultimately, the medical establishment largely ignored the surge in ME/CFS in the mid-1980s — effectively disappearing an epidemic.

Long COVID entered the picture after the COVID-19 pandemic began in 2020. Doctors and patients themselves began comparing the symptom constellation to that of ME/CFS and noting striking similarities. As a result, some scientists, medical professionals and long COVID patients have suggested that ME/CFS is a “subset” of long COVID or, more confusingly, that some cases of long COVID actually are ME/CFS.

The fact is, it’s unclear how similar these maladies are at the biochemical level. We need to find out. SARS-COV-2 has been found to persist in the body long after the acute infection. If persistent virus causes most cases of long COVID, eradicating it from patients has little chance of helping ME/CFS patients. SARS-COV-2 could not possibly have caused any of the multi-millions of cases of ME/CFS prior to 2020.

As Monica Bertagnolli, MDthe new NIH director said recently, “…I don’t think you can ever assume that one virus is going to act like another. Certainly, every virus that we know of seems to have a different effect in the body long term.”

Nevertheless, there are some intriguing overlaps in symptoms, suggesting that physiological features of the disruptions occurring in these diseases may be shared. New drugs that can improve symptoms such as ones affecting brain function, muscle function or circulation, for example — might benefit both types of patients. But for any underlying causes that differ between ME/CFS and long COVID,…



Read More: Sanders’ long COVID funding bill misses opportunity to aid a similar chronic

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.